Solacium and Creo Pharmaceuticals have both been acquired less than a year after the move to Advent International
Czech pharmaceutical company Zentiva split from Sanofi in 2018, moving to Advent International. Soon after in March, the company made its first acquisition taking over ownership of Solacium from Siyiara Enterprises and Trasca Alexandru-Tony. Solacium produces generics in Romania, the same role that Zentiva played for Sanofi in Europe.
Now, Zentiva Group is announcing the acquisition of another generics producer, Creo Pharmaceuticals, a subsidiary of Amneal Pharmaceuticals for its commercial operations in the UK.
Nick Haggar, CEO of Zentiva stated: “Zentiva is delighted to confirm the acquisition of Creo Pharma which will strengthen Zentiva’s position in the UK.”
Haggar added: “This move reflects our confidence in the UK and our deep commitment to the development, manufacture and supply of high-quality affordable medicines.”
Luke Hart, Managing Director of Creo echoed this, saying the combination of the businesses will bring value to customers and patients in the UK while accelerating both companies.
Zentiva's acquisitions of two generics-focused producers in this short space of time bodes well for Zentiva so soon after a major change in leadership.